navy-cuv-logo-rgb-1200x628px.png
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
28. März 2024 04:25 ET | Clinuvel Pharmaceuticals Limited
Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing in Dusseldorf, Germany.
navy-cuv-logo-rgb-1200x628px.png
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
04. März 2024 21:38 ET | Clinuvel Pharmaceuticals Limited
CLINUVEL joined an intimate evening at Lady Gaga and Michael Polansky's Malibu home to celebrate the future of photomedicine
CLINUVEL's CYACÊLLE
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
28. Februar 2023 18:58 ET | Clinuvel Pharmaceuticals Limited
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level...
CLINUVEL Financial Performance
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
23. Februar 2023 18:14 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Executive summaryPositive Results in the Half Year to 31 December 2022 19% increase in revenues from clinical demand for SCENESSE®...
Full Latin without Latin logo.png
CLINUVEL Trial Results Show Drug Reduces DNA Damage
15. Januar 2023 18:23 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Results from a clinical trial in a genetic DNA repair disorder show that a new drug – afamelanotide – may be able to reduce the development of...
Full Latin without Latin logo.png
Letter to shareholders from CLINUVEL’s CEO
29. April 2022 01:20 ET | Clinuvel Pharmaceuticals Limited
LONDON, April 29, 2022 (GLOBE NEWSWIRE) --       Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on...
Figure 1: SCENESSE® connects the dots
CLINUVEL progresses innovative DNA Repair Program
10. September 2020 03:18 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE® (afamelanotide 16mg) to treat the disease xeroderma...
VALLAURIX Lab
CLINUVEL Opens VALLAURIX R&D Centre In Singapore
31. August 2020 05:35 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, Aug. 31, 2020 (GLOBE NEWSWIRE) -- The CLINUVEL Group today announced the opening of its state-of-the-art centralised Research & Development Centre in...
Melanocortin system and afamelanotide
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
13. Juli 2020 03:38 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...
Full Latin without Latin logo.png
SCENESSE® to be Prescribed in China
23. April 2020 02:08 ET | Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the...